Navoximod is primarily investigated for its potential in cancer immunotherapy. It works as an IDO1 enzyme inhibitor, which plays a role in suppressing the immune system's ability to attack cancer cells. By blocking IDO1, Navoximod helps to enhance the immune response against tumors, making it a promising candidate for combination therapies with other immunotherapeutic agents like checkpoint inhibitors. Its application is being studied in clinical trials to evaluate its efficacy in treating various cancers, including melanoma and solid tumors. Researchers are also exploring its potential to improve outcomes in patients who have shown resistance to conventional treatments.